Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 7
2005 3
2006 1
2007 4
2009 8
2010 5
2011 5
2012 2
2013 5
2014 4
2015 1
2017 1
2018 1
2019 3
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Cancer immunoprevention.
Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P. Lollini PL, et al. Among authors: de giovanni c. Future Oncol. 2005 Feb;1(1):57-66. doi: 10.1517/14796694.1.1.57. Future Oncol. 2005. PMID: 16555976 Review.
Preclinical vaccines against mammary carcinoma.
Lollini PL, Cavallo F, De Giovanni C, Nanni P. Lollini PL, et al. Among authors: de giovanni c. Expert Rev Vaccines. 2013 Dec;12(12):1449-63. doi: 10.1586/14760584.2013.845530. Expert Rev Vaccines. 2013. PMID: 24195482 Free article. Review.
Oncolytic herpes virus retargeted to HER-2.
Lollini PL, Menotti L, De Giovanni C, Campadelli-Fiume G, Nanni P. Lollini PL, et al. Among authors: de giovanni c. Cell Cycle. 2009 Sep 15;8(18):2859-60. doi: 10.4161/cc.8.18.9368. Epub 2009 Sep 26. Cell Cycle. 2009. PMID: 19729994 No abstract available.
Molecular and cellular biology of rhabdomyosarcoma.
De Giovanni C, Landuzzi L, Nicoletti G, Lollini PL, Nanni P. De Giovanni C, et al. Future Oncol. 2009 Nov;5(9):1449-75. doi: 10.2217/fon.09.97. Future Oncol. 2009. PMID: 19903072 Review.
Vaccines and other immunological approaches for cancer immunoprevention.
Lollini PL, Nicoletti G, Landuzzi L, Cavallo F, Forni G, De Giovanni C, Nanni P. Lollini PL, et al. Among authors: de giovanni c. Curr Drug Targets. 2011 Dec;12(13):1957-73. doi: 10.2174/138945011798184146. Curr Drug Targets. 2011. PMID: 21158706 Review.
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.
De Giovanni C, Landuzzi L, Palladini A, Ianzano ML, Nicoletti G, Ruzzi F, Amici A, Croci S, Nanni P, Lollini PL. De Giovanni C, et al. Cancers (Basel). 2019 Apr 11;11(4):517. doi: 10.3390/cancers11040517. Cancers (Basel). 2019. PMID: 30979001 Free PMC article.
Rethinking herpes simplex virus: the way to oncolytic agents.
Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L. Campadelli-Fiume G, et al. Among authors: de giovanni c. Rev Med Virol. 2011 Jul;21(4):213-26. doi: 10.1002/rmv.691. Epub 2011 May 27. Rev Med Virol. 2011. PMID: 21626603 Review.
The molecular basis of herpesviruses as oncolytic agents.
Menotti L, Campadelli-Fiume G, Nanni P, Lollini PL, De Giovanni C. Menotti L, et al. Among authors: de giovanni c. Curr Pharm Biotechnol. 2012 Jul;13(9):1795-803. doi: 10.2174/138920112800958931. Curr Pharm Biotechnol. 2012. PMID: 21740356 Review.
58 results